desmethylclomipramine and Panic-Disorder

desmethylclomipramine has been researched along with Panic-Disorder* in 2 studies

Trials

2 trial(s) available for desmethylclomipramine and Panic-Disorder

Article	Year
Serum levels of clomipramine and desmethylclomipramine and clinical improvement in panic disorder. Journal of psychopharmacology (Oxford, England), 1999, Volume: 13, Issue:1 Several placebo-controlled trials have shown the efficacy of clomipramine (CMI) in panic disorder. However, none has investigated the relationship between CMI, and desmethylclomipramine (DCMI) plasma levels, and outcome. In this trial, 41 patients meeting the DSM-III-R criteria for panic disorder with/without agoraphobia received 50-200 mg of CMI daily in a single-blind, flexible dose regimen for 14 weeks. At the end of treatment, 97% of the patients were free of panic attacks. Patients were classified into two groups of improvement according to the panic symptom items of the 'Patient-Rated Anxiety Scale'. A repeated-measures analysis of variance suggested a significant association between outcome and serum DCMI level/daily dose ratio as well as total serum level/daily dose. Patients with intense improvement showed DCMI and total serum levels lower than those with moderate improvement. The results indicate the importance of monitoring clomipramine and desmethylclomipramine serum levels in this disorder. Topics: Adult; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Male; Middle Aged; Panic Disorder; Psychiatric Status Rating Scales; Single-Blind Method	1999
Increased antipanic efficacy in combined treatment with clomipramine and dixyrazine. Acta psychiatrica Scandinavica, 1994, Volume: 89, Issue:4 A double-blind 12 week trial was undertaken to compare the effects of clomipramine + dixyrazine with clomipramine + placebo in the treatment of panic disorder with or without agoraphobia. Of 45 patients included (21 dixyrazine, 24 placebo), 16 dropped out (6 dixyrazine, 10 placebo). The number of panic attacks and the scores on the panic disorder subscale of the Hamilton Anxiety Rating Scale were significantly reduced in response to both treatment regimens, but the reduction was significantly greater in the dixyrazine group. The patients' daily functioning was significantly more improved with the dixyrazine combination. The serum concentration of desmethylclomipramine monotherapy was significantly higher and the side effects significantly lower in the combined treatment with dixyrazine than with clomipramine monotherapy. Clomipramine combined with dixyrazine seems superior to clomipramine in the treatment of panic disorder. Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clomipramine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Panic Disorder; Phenothiazines; Placebos; Psychiatric Status Rating Scales; Stimulation, Chemical; Treatment Outcome	1994

Article

Year

Serum levels of clomipramine and desmethylclomipramine and clinical improvement in panic disorder.

Journal of psychopharmacology (Oxford, England), 1999, Volume: 13, Issue:1

Several placebo-controlled trials have shown the efficacy of clomipramine (CMI) in panic disorder. However, none has investigated the relationship between CMI, and desmethylclomipramine (DCMI) plasma levels, and outcome. In this trial, 41 patients meeting the DSM-III-R criteria for panic disorder with/without agoraphobia received 50-200 mg of CMI daily in a single-blind, flexible dose regimen for 14 weeks. At the end of treatment, 97% of the patients were free of panic attacks. Patients were classified into two groups of improvement according to the panic symptom items of the 'Patient-Rated Anxiety Scale'. A repeated-measures analysis of variance suggested a significant association between outcome and serum DCMI level/daily dose ratio as well as total serum level/daily dose. Patients with intense improvement showed DCMI and total serum levels lower than those with moderate improvement. The results indicate the importance of monitoring clomipramine and desmethylclomipramine serum levels in this disorder.

Topics: Adult; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Male; Middle Aged; Panic Disorder; Psychiatric Status Rating Scales; Single-Blind Method

1999

Increased antipanic efficacy in combined treatment with clomipramine and dixyrazine.

Acta psychiatrica Scandinavica, 1994, Volume: 89, Issue:4

A double-blind 12 week trial was undertaken to compare the effects of clomipramine + dixyrazine with clomipramine + placebo in the treatment of panic disorder with or without agoraphobia. Of 45 patients included (21 dixyrazine, 24 placebo), 16 dropped out (6 dixyrazine, 10 placebo). The number of panic attacks and the scores on the panic disorder subscale of the Hamilton Anxiety Rating Scale were significantly reduced in response to both treatment regimens, but the reduction was significantly greater in the dixyrazine group. The patients' daily functioning was significantly more improved with the dixyrazine combination. The serum concentration of desmethylclomipramine monotherapy was significantly higher and the side effects significantly lower in the combined treatment with dixyrazine than with clomipramine monotherapy. Clomipramine combined with dixyrazine seems superior to clomipramine in the treatment of panic disorder.

Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clomipramine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Panic Disorder; Phenothiazines; Placebos; Psychiatric Status Rating Scales; Stimulation, Chemical; Treatment Outcome

1994